At the recent 2022 American Society of Clinical Oncology(ASCO)annual meeting,the latest progress was presented in clinical trials of various therapeutic modalities for adult soft tissue sarcoma(STS),including chemothe...At the recent 2022 American Society of Clinical Oncology(ASCO)annual meeting,the latest progress was presented in clinical trials of various therapeutic modalities for adult soft tissue sarcoma(STS),including chemotherapy,targeted therapy,anti-immune checkpoint immunotherapy,and multiple combination treatments(Table 1).Generally,the development of clinical treatments for STS is relatively slow,owing to the complex pathological subtypes of sarcoma and their heterogeneous biological behaviors.Here,we briefly summarize updates from this year’s ASCO meeting and discuss the future therapeutic perspectives for unspecific STS.展开更多
BACKGROUND Melanoma is a highly malignant skin tumour, and is one of the most rapidly growing malignant tumors in recent years. According to statistics, the morbidity of cancer increases with age, accounting for 1.6% ...BACKGROUND Melanoma is a highly malignant skin tumour, and is one of the most rapidly growing malignant tumors in recent years. According to statistics, the morbidity of cancer increases with age, accounting for 1.6% of new cancer cases and 0.6% of deaths worldwide. Melanoma has a serious impact on society and families, thus it is of great significance to find biological markers related to the diagnosis and treatment of melanoma.AIM To explore the expression and predictive value of mir-489 and mir-21 in melanoma metastasis.METHODS A total of 60 patients with malignant melanoma treated at our hospital from June2017 to December 2018 were selected as a research group, while 40 healthy subjects were selected as a control group. qRT-PCR technique was used to detect miR-489 and miR-21 in serum of the two groups. ROC curve was drawn to evaluate the predictive value and diagnostic efficiency. Spearman test was used for correlation analysis. Logistic single-and multiple-factor analyses were performed to identify the risk factors related to melanoma metastasis.RESULTS The expression of miR-489 in the research group was significantly lower than that in the control group(P < 0.001). However, the expression of miR-21 in the research group was significantly higher than that in the control group(P < 0.001).The expression of miR-489 and miR-21 was related to TNM stage and metastasis(P < 0.001). In the diagnosis of melanoma patients, the sensitivity, specificity, and AUC of miR-489 alone were 75.56%, 80.00%, and 0.852, respectively. The sensitivity, specificity, and AUC of miR-21 alone were 77.78%, 82.22%, and 0.844,respectively. MiR-489 was negatively correlated with TNM stage of melanoma(r=-0.612, P < 0.001), while miR-21 was positively correlated with TNM stage(r =0.609, P < 0.001). Logistic single-and multiple-factor regression analyses showed that TNM stage, miR-489, and mir-21 were independent risk factors for malignant melanoma metastasis.CONCLUSION MiR-489 and miR-21 may participate in the process of melanoma occurrence,development, and metastasis, and can be used as potential serum biomarkers for melanoma metastasis diagnosis and disease assessment.展开更多
文摘At the recent 2022 American Society of Clinical Oncology(ASCO)annual meeting,the latest progress was presented in clinical trials of various therapeutic modalities for adult soft tissue sarcoma(STS),including chemotherapy,targeted therapy,anti-immune checkpoint immunotherapy,and multiple combination treatments(Table 1).Generally,the development of clinical treatments for STS is relatively slow,owing to the complex pathological subtypes of sarcoma and their heterogeneous biological behaviors.Here,we briefly summarize updates from this year’s ASCO meeting and discuss the future therapeutic perspectives for unspecific STS.
文摘BACKGROUND Melanoma is a highly malignant skin tumour, and is one of the most rapidly growing malignant tumors in recent years. According to statistics, the morbidity of cancer increases with age, accounting for 1.6% of new cancer cases and 0.6% of deaths worldwide. Melanoma has a serious impact on society and families, thus it is of great significance to find biological markers related to the diagnosis and treatment of melanoma.AIM To explore the expression and predictive value of mir-489 and mir-21 in melanoma metastasis.METHODS A total of 60 patients with malignant melanoma treated at our hospital from June2017 to December 2018 were selected as a research group, while 40 healthy subjects were selected as a control group. qRT-PCR technique was used to detect miR-489 and miR-21 in serum of the two groups. ROC curve was drawn to evaluate the predictive value and diagnostic efficiency. Spearman test was used for correlation analysis. Logistic single-and multiple-factor analyses were performed to identify the risk factors related to melanoma metastasis.RESULTS The expression of miR-489 in the research group was significantly lower than that in the control group(P < 0.001). However, the expression of miR-21 in the research group was significantly higher than that in the control group(P < 0.001).The expression of miR-489 and miR-21 was related to TNM stage and metastasis(P < 0.001). In the diagnosis of melanoma patients, the sensitivity, specificity, and AUC of miR-489 alone were 75.56%, 80.00%, and 0.852, respectively. The sensitivity, specificity, and AUC of miR-21 alone were 77.78%, 82.22%, and 0.844,respectively. MiR-489 was negatively correlated with TNM stage of melanoma(r=-0.612, P < 0.001), while miR-21 was positively correlated with TNM stage(r =0.609, P < 0.001). Logistic single-and multiple-factor regression analyses showed that TNM stage, miR-489, and mir-21 were independent risk factors for malignant melanoma metastasis.CONCLUSION MiR-489 and miR-21 may participate in the process of melanoma occurrence,development, and metastasis, and can be used as potential serum biomarkers for melanoma metastasis diagnosis and disease assessment.
